pravastatin has been researched along with Hypertrophy, Right Ventricular in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bardou, M; Dumas, M; Goirand, F; Guerard, P; Lirussi, F; Rakotoniaina, Z; Rochette, L | 1 |
1 other study(ies) available for pravastatin and Hypertrophy, Right Ventricular
| Article | Year |
|---|---|
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
Topics: Acetylcholine; Animals; Apoptosis; Blood Pressure; Blotting, Western; Body Weight; Caspase 3; Disease Progression; Endothelial Cells; Heart Function Tests; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Immunohistochemistry; In Situ Nick-End Labeling; Lung; Male; Monocrotaline; Nitric Oxide Synthase Type III; Nitroprusside; Poisons; Pravastatin; Pulmonary Artery; Rats; Rats, Wistar; Survival; Vasodilator Agents | 2006 |